The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
January 10th 2025
Respiratory patterns and submental surface electromyography may be a reliable indicator of dysphagia among patients with myasthenia gravis.
Molecular Profiling Identifies Potential Prognostic Biomarker for Treatment Response in HNSCC
January 6th 2022Human papillomavirus surrogate marker p16 was identified as a potential prognostic biomarker for standard-of-care immune checkpoint blockade therapy response in non-oropharyngeal head and neck squamous cell carcinoma.
Read More
Ponatinib, High-Dose Chemo Combo Likely to Benefit High-risk BP-CML
January 1st 2022Survival rates for patients with blast-phase chronic myeloid leukemia (BP-CML) are notoriously poor, necessitating effective treatments to fill the care gap for this group who often survive less than 1 year.
Read More
Ketogenic Diet Shows Promise as Nonpharmacologic Treatment for PCOS
December 31st 2021With a top treatment recommendation for obese women with polycystic ovary syndrome (PCOS) comprising lifestyle changes via diet changes and physical activity, this study’s investigators evaluated the effects of a ketogenic diet among this patient population.
Read More
Could GLP-1 RAs Improve COVID-19-Induced Pulmonary Arterial Hypertension?
December 30th 2021Recent studies show that glucagon-like peptide-1 receptor agonists have anti-inflammatory effects in human and rodent pathological models, making them a potential therapeutic strategy for treating pulmonary arterial hypertension after COVID-19 infection.
Read More
Leveraging Real-World Data at Emory Healthcare
December 28th 2021Ryan Haumschild, PharmD, MS, MBA discusses the potential to lower total costs through care pathways designed to start patients with plaque psoriasis and metabolic syndrome on treatments that have shown to have better overall outcomes, such as tildrakizumab.
Watch